HEADER TRANSFERASE 15-OCT-08 2W17 TITLE CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE, COMPOUND (S)-8B COMPND MOL_ID: 1; COMPND 2 MOLECULE: CELL DIVISION PROTEIN KINASE 2; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: CYCLIN DEPENDENT KINASE 2, P33 PROTEIN KINASE; COMPND 5 EC: 2.7.11.22; COMPND 6 ENGINEERED: YES; COMPND 7 OTHER_DETAILS: ACETYLATION AT N-TERMINAL METHIONINE SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 7108; SOURCE 7 EXPRESSION_SYSTEM_CELL_LINE: SF21; SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS KEYWDS KINASE, MITOSIS, CELL CYCLE, TRANSFERASE, SERINE/THREONINE-PROTEIN KEYWDS 2 KINASE, ATP-BINDING, CELL DIVISION, PHOSPHOPROTEIN, PHOSPHORYLATION, KEYWDS 3 NUCLEOTIDE-BINDING EXPDTA X-RAY DIFFRACTION AUTHOR C.D.JONES,D.M.ANDREWS,A.J.BARKER,K.BLADES,P.DAUNT,S.EAST,C.GEH, AUTHOR 2 M.A.GRAHAM,K.M.JOHNSON,S.A.LODDICK,H.M.MCFARLAND,A.MCGREGOR,L.MOSS, AUTHOR 3 D.A.RUDGE,P.B.SIMPSON,M.L.SWAIN,K.Y.TAM,J.A.TUCKER,M.WALKER, AUTHOR 4 C.BRASSINGTON,H.HAYE,E.MCCALL REVDAT 6 16-OCT-24 2W17 1 REMARK REVDAT 5 01-MAY-24 2W17 1 REMARK REVDAT 4 24-APR-19 2W17 1 SOURCE LINK REVDAT 3 13-JUL-11 2W17 1 VERSN REVDAT 2 02-DEC-08 2W17 1 VERSN JRNL REVDAT 1 04-NOV-08 2W17 0 JRNL AUTH C.D.JONES,D.M.ANDREWS,A.J.BARKER,K.BLADES,P.DAUNT,S.EAST, JRNL AUTH 2 C.GEH,M.A.GRAHAM,K.M.JOHNSON,S.A.LODDICK,H.M.MCFARLAND, JRNL AUTH 3 A.MCGREGOR,L.MOSS,D.A.RUDGE,P.B.SIMPSON,M.L.SWAIN,K.Y.TAM, JRNL AUTH 4 J.A.TUCKER,M.WALKER JRNL TITL THE DISCOVERY OF AZD5597, A POTENT IMIDAZOLE PYRIMIDINE JRNL TITL 2 AMIDE CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING. JRNL REF BIOORG.MED.CHEM.LETT. V. 18 6369 2008 JRNL REFN ISSN 0960-894X JRNL PMID 18996007 JRNL DOI 10.1016/J.BMCL.2008.10.102 REMARK 2 REMARK 2 RESOLUTION. 2.15 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.2.0005 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.15 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 42.93 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 99.7 REMARK 3 NUMBER OF REFLECTIONS : 15562 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.244 REMARK 3 R VALUE (WORKING SET) : 0.242 REMARK 3 FREE R VALUE : 0.300 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.060 REMARK 3 FREE R VALUE TEST SET COUNT : 779 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 9.39 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 42.93 REMARK 3 REFLECTION IN BIN (WORKING SET) : 212 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.2340 REMARK 3 BIN FREE R VALUE SET COUNT : 11 REMARK 3 BIN FREE R VALUE : 0.1230 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2209 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 37 REMARK 3 SOLVENT ATOMS : 150 REMARK 3 REMARK 3 B VALUES. REMARK 3 B VALUE TYPE : LIKELY RESIDUAL REMARK 3 FROM WILSON PLOT (A**2) : 31.00 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 39.93 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.07300 REMARK 3 B22 (A**2) : 2.66000 REMARK 3 B33 (A**2) : -2.58700 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.361 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.265 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.222 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 18.610 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.941 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.923 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 2310 ; 0.012 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): 1562 ; 0.004 ; 0.020 REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 3137 ; 1.427 ; 2.000 REMARK 3 BOND ANGLES OTHERS (DEGREES): 3814 ; 0.914 ; 3.000 REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 275 ; 6.473 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 92 ;39.297 ;23.261 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 392 ;16.179 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 13 ;22.593 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 354 ; 0.077 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 2518 ; 0.006 ; 0.021 REMARK 3 GENERAL PLANES OTHERS (A): 453 ; 0.001 ; 0.020 REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 480 ; 0.214 ; 0.200 REMARK 3 NON-BONDED CONTACTS OTHERS (A): 1555 ; 0.181 ; 0.200 REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): 1120 ; 0.179 ; 0.200 REMARK 3 NON-BONDED TORSION OTHERS (A): 1109 ; 0.088 ; 0.200 REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 122 ; 0.190 ; 0.200 REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 18 ; 0.118 ; 0.200 REMARK 3 SYMMETRY VDW OTHERS (A): 40 ; 0.176 ; 0.200 REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 20 ; 0.235 ; 0.200 REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 1403 ; 0.605 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 2266 ; 1.089 ; 2.000 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 907 ; 1.332 ; 3.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 871 ; 2.119 ; 4.500 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : BABINET MODEL PLUS MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.40 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS. DISORDERED REGIONS WERE OMITTED FROM THE MODEL, REMARK 3 DISORDERED SIDE-CHAINS WERE TRUNCATED TO C-BETA. REMARK 4 REMARK 4 2W17 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 15-OCT-08. REMARK 100 THE DEPOSITION ID IS D_1290037770. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 15-DEC-05 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 7.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU MICROMAX-007 REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.54 REMARK 200 MONOCHROMATOR : GRAPHITE REMARK 200 OPTICS : CONFOCAL MIRRORS (VARIMAX) REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : RIGAKU SATURN 92 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : CRYSTALCLEAR REMARK 200 DATA SCALING SOFTWARE : CRYSTALCLEAR REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 15575 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.150 REMARK 200 RESOLUTION RANGE LOW (A) : 50.770 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 3.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.7 REMARK 200 DATA REDUNDANCY : 3.330 REMARK 200 R MERGE (I) : 0.10000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 6.0000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.15 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.23 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.9 REMARK 200 DATA REDUNDANCY IN SHELL : 3.30 REMARK 200 R MERGE FOR SHELL (I) : 0.39000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.100 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: INTERNAL CDK2 STRUCTURE MODEL REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 40.30 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.06 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 8% PEG 3350, 0.1M HEPES PH 7.5, 0.05M REMARK 280 AMMONIUM ACETATE REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 26.77100 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 35.88550 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 35.91200 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 35.88550 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 26.77100 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 35.91200 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 13 REMARK 465 THR A 39 REMARK 465 GLU A 40 REMARK 465 THR A 41 REMARK 465 GLU A 42 REMARK 465 GLY A 43 REMARK 465 ASN A 74 REMARK 465 ARG A 150 REMARK 465 ALA A 151 REMARK 465 PHE A 152 REMARK 465 GLY A 153 REMARK 465 VAL A 154 REMARK 465 PRO A 155 REMARK 465 VAL A 156 REMARK 465 ARG A 157 REMARK 465 THR A 158 REMARK 465 TYR A 159 REMARK 465 THR A 160 REMARK 465 HIS A 161 REMARK 465 GLU A 162 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 MET A 1 CG SD CE REMARK 470 GLU A 12 CG CD OE1 OE2 REMARK 470 THR A 14 OG1 CG2 REMARK 470 TYR A 15 CG CD1 CD2 CE1 CE2 CZ OH REMARK 470 LYS A 34 CE NZ REMARK 470 ARG A 36 CG CD NE CZ NH1 NH2 REMARK 470 ASP A 38 CG OD1 OD2 REMARK 470 GLU A 57 CD OE1 OE2 REMARK 470 LYS A 75 CG CD CE NZ REMARK 470 VAL A 164 CG1 CG2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15 REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375 REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS. REMARK 500 REMARK 500 DISTANCE CUTOFF: REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE REMARK 500 O HOH A 2012 O HOH A 2123 2564 2.05 REMARK 500 OE2 GLU A 73 ND2 ASN A 272 2464 2.15 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ARG A 36 77.33 -41.69 REMARK 500 LEU A 37 168.92 -30.07 REMARK 500 THR A 72 106.30 -165.69 REMARK 500 GLU A 81 131.33 -36.97 REMARK 500 ALA A 95 1.50 -68.12 REMARK 500 ARG A 126 -13.15 82.47 REMARK 500 ASP A 127 51.82 -151.21 REMARK 500 TYR A 179 63.00 -109.36 REMARK 500 PRO A 254 48.63 -108.42 REMARK 500 ASP A 288 33.85 -98.84 REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A2015 DISTANCE = 7.71 ANGSTROMS REMARK 525 HOH A2016 DISTANCE = 5.94 ANGSTROMS REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ACE A 0 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ACT A1299 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE I19 A1300 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1PYE RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR REMARK 900 RELATED ID: 1H08 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 2VTH RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1V1K RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 2B53 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN-234325 REMARK 900 RELATED ID: 1H25 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1OKV RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ILE-PHE-NH2 REMARK 900 RELATED ID: 1KE7 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1, REMARK 900 3-DIHYDRO-2- BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3- OXAZOL-5-YL)- REMARK 900 1,3-DIHYDRO-2H-INDOL-2- ONE REMARK 900 RELATED ID: 1PXK RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)PYRIMIDIN-2-YL]-N'- HYDROXYIMINOFORMAMIDE REMARK 900 RELATED ID: 2BHH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 4- HYDROXYPIPERINDINESULFONYL-INDIRUBINE REMARK 900 RELATED ID: 2UUE RELATED DB: PDB REMARK 900 REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE REMARK 900 INHIBITORS REMARK 900 RELATED ID: 2VTA RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1GZ8 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2- REMARK 900 AMINO-6-(3'-METHYL- 2'-OXO)BUTOXYPURINE REMARK 900 RELATED ID: 1E1V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058 REMARK 900 RELATED ID: 1OL2 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1H27 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P27 REMARK 900 RELATED ID: 1JSV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH 4- REMARK 900 [(6-AMINO-4- PYRIMIDINYL)AMINO]BENZENESULFONAMIDE REMARK 900 RELATED ID: 2B52 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH-042562 REMARK 900 RELATED ID: 1KE5 RELATED DB: PDB REMARK 900 CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO- 1,2-DIHYDRO-3H-INDOL-3- REMARK 900 YLIDENE)METHYL] AMINO}BENZENESULFONAMIDE REMARK 900 RELATED ID: 1FIN RELATED DB: PDB REMARK 900 CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX REMARK 900 RELATED ID: 2C5O RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C68 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1P2A RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH REMARK 900 ATRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR REMARK 900 RELATED ID: 2VTT RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2C4G RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514 REMARK 900 RELATED ID: 2VTQ RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1W0X RELATED DB: PDB REMARK 900 CRYSTALS STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR REMARK 900 OLOMOUCINE. REMARK 900 RELATED ID: 1H1Q RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6094 REMARK 900 RELATED ID: 2W05 RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE, REMARK 900 COMPOUND 5B REMARK 900 RELATED ID: 1PXO RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2- REMARK 900 AMINO-4-METHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-(3-NITRO- PHENYL)- REMARK 900 AMINE REMARK 900 RELATED ID: 1KE9 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({ REMARK 900 [AMINO(IMINO)METHYL] AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3- REMARK 900 DIHYDRO-1H-INDOLE REMARK 900 RELATED ID: 2A0C RELATED DB: PDB REMARK 900 HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II, A NOVEL 2,6,9- REMARK 900 TRISUBSTITUTED PURINE CYCLIN -DEPENDENT KINASE INHIBITOR REMARK 900 RELATED ID: 1HCK RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1JSU RELATED DB: PDB REMARK 900 P27(KIP1)/CYCLIN A/CDK2 COMPLEX REMARK 900 RELATED ID: 1PXN RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-[4-(4- REMARK 900 METHYL-2- METHYLAMINO-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL REMARK 900 RELATED ID: 2UZE RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2VTM RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2V0D RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1OIQ RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1H1R RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6086 REMARK 900 RELATED ID: 2IW8 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A F82H-L83V-H84D REMARK 900 MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR REMARK 900 RELATED ID: 1GIH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1PW2 RELATED DB: PDB REMARK 900 APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1HCL RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 2VTN RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2W06 RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE, REMARK 900 COMPOUND 5C REMARK 900 RELATED ID: 1JST RELATED DB: PDB REMARK 900 PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A REMARK 900 RELATED ID: 1OIU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 1B38 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1PXM RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 3-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINO]-PHENOL REMARK 900 RELATED ID: 1FQ1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) INCOMPLEX REMARK 900 WITH PHOSPHO-CDK2 REMARK 900 RELATED ID: 1VYW RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137 REMARK 900 RELATED ID: 1H1P RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU2058 REMARK 900 RELATED ID: 2C69 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1URC RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-ARG- ARG-LEU-ASN-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1PXI RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,5- REMARK 900 DICHLORO-THIOPHEN- 3-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 2C6I RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1YKR RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINEINHIBITOR REMARK 900 RELATED ID: 2UZD RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2C5Y RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C6K RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1WCC RELATED DB: PDB REMARK 900 SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY REMARK 900 RELATED ID: 2J9M RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC REMARK 900 AMINOPYRIMIDINE REMARK 900 RELATED ID: 1VYZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227 REMARK 900 RELATED ID: 2VTI RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1JVP RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 ( UNPHOSPHORYLATED) INCOMPLEX WITH REMARK 900 PKF049-365 REMARK 900 RELATED ID: 1W98 RELATED DB: PDB REMARK 900 THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E REMARK 900 RELATED ID: 1PKD RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN REMARK 900 A REMARK 900 RELATED ID: 1P5E RELATED DB: PDB REMARK 900 THE STRUCURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THEINHIBITOR REMARK 900 4,5,6,7- TETRABROMOBENZOTRIAZOLE (TBS) REMARK 900 RELATED ID: 2VTS RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2C5P RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2UZN RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2B54 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2) COMPLEXED WITH DIN-232305 REMARK 900 RELATED ID: 1PXJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR 4-(2,4- REMARK 900 DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YLAMINE REMARK 900 RELATED ID: 1KE6 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7- REMARK 900 OXO-6,7-DIHYDRO -8H-[1,3]THIAZOLO[5,4-E]INDOL-8- YLIDENE)HYDRAZINO] REMARK 900 PHENYL}METHANESULFONAMIDE REMARK 900 RELATED ID: 2UZL RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 2CCI RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A REMARK 900 PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6 REMARK 900 RELATED ID: 2G9X RELATED DB: PDB REMARK 900 STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/ CYCLIN A INCOMPLEX WITH REMARK 900 THE INHIBITOR NU6271 REMARK 900 RELATED ID: 2BKZ RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611 REMARK 900 RELATED ID: 1Y91 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A] REMARK 900 PYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2IW6 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A COMPLEXED WITH A REMARK 900 BISANILINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1GIJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1R78 RELATED DB: PDB REMARK 900 CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1H0V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[(R )-PYRROLIDINO-5'-YL]METHOXYPURINE REMARK 900 RELATED ID: 2IW9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2- CYCLIN A COMPLEXED WITH A REMARK 900 BISANILINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1W8C RELATED DB: PDB REMARK 900 CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY- 8-ISOPROPYL-9H-PURIN-2- REMARK 900 YLAMINE AND MONOMERIC CDK2 REMARK 900 RELATED ID: 1BUH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITHCELL CYCLE- REMARK 900 REGULATORY PROTEIN CKSHS1 REMARK 900 RELATED ID: 2BPM RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529 REMARK 900 RELATED ID: 2BTS RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032 REMARK 900 RELATED ID: 1FVV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLEINHIBITOR REMARK 900 RELATED ID: 1OKW RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR AC-ARG- ARG-LEU-ASN-(M-CL-PHE)-NH2 REMARK 900 RELATED ID: 2VTP RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2A4L RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE REMARK 900 RELATED ID: 2C6T RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1FVT RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH AN REMARK 900 OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1QMZ RELATED DB: PDB REMARK 900 PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX REMARK 900 RELATED ID: 2VU3 RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2B55 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITHINDENOPYRAXOLE REMARK 900 DIN-101312 REMARK 900 RELATED ID: 1OGU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 2- REMARK 900 ARYLAMINO-4- CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1PF8 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2COMPLEXED WITH REMARK 900 A NUCLEOSIDE INHIBITOR REMARK 900 RELATED ID: 1H1S RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6102 REMARK 900 RELATED ID: 2JGZ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B REMARK 900 RELATED ID: 2C5V RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2BHE RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 5-BROMO- INDIRUBINE REMARK 900 RELATED ID: 1URW RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH AN IMIDAZO[1,2-B] PYRIDAZINE REMARK 900 RELATED ID: 1OIY RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 2C6L RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1F5Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO REMARK 900 HUMAN CYCLIN DEPENDANT KINASE 2 REMARK 900 RELATED ID: 2C6O RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 2VTL RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1OL1 RELATED DB: PDB REMARK 900 CYCLIN A BINDING GROOVE INHIBITOR H-CIT- CIT-LEU-ILE-(P-F-PHE)-NH2 REMARK 900 RELATED ID: 1H01 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 2UZB RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1OIR RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1OI9 RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 6- REMARK 900 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR REMARK 900 RELATED ID: 2VTJ RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 2CJM RELATED DB: PDB REMARK 900 MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 REMARK 900 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE REMARK 900 RELATED ID: 2C5N RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C5X RELATED DB: PDB REMARK 900 DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 REMARK 900 PROVIDES INSIGHTS FOR DRUG DESIGN REMARK 900 RELATED ID: 2C6M RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE REMARK 900 TRIAZOLOPYRIMIDINE INHIBITOR REMARK 900 RELATED ID: 1OIT RELATED DB: PDB REMARK 900 IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT REMARK 900 KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION REMARK 900 RELATED ID: 1GY3 RELATED DB: PDB REMARK 900 PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE REMARK 900 RELATED ID: 2V22 RELATED DB: PDB REMARK 900 REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE REMARK 900 INHIBITORS REMARK 900 RELATED ID: 1GII RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1DI8 RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4- REMARK 900 [3- HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE REMARK 900 RELATED ID: 2VV9 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE REMARK 900 RELATED ID: 1E9H RELATED DB: PDB REMARK 900 THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE REMARK 900 INHIBITOR INDIRUBIN-5- SULPHONATE BOUND REMARK 900 RELATED ID: 2VTO RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1DM2 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 HYMENIALDISINE REMARK 900 RELATED ID: 1H24 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 2UZO RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE REMARK 900 INHIBITOR REMARK 900 RELATED ID: 1H00 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 2EXM RELATED DB: PDB REMARK 900 HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE REMARK 900 RELATED ID: 2CLX RELATED DB: PDB REMARK 900 4-ARYLAZO-3,5-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY, REMARK 900 CRYSTAL STRUCTURE IN COMPLEX WITH CDK2, SELECTIVITY, AND CELLULAR REMARK 900 EFFECTS REMARK 900 RELATED ID: 1PXP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR N-[4-(2, REMARK 900 4-DIMETHYL- THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'- DIMETHYL-BENZENE-1, REMARK 900 4-DIAMINE REMARK 900 RELATED ID: 2CCH RELATED DB: PDB REMARK 900 THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE REMARK 900 PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA-LINKED ATP ANALOGUE REMARK 900 RELATED ID: 2BTR RELATED DB: PDB REMARK 900 STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873 REMARK 900 RELATED ID: 1B39 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160 REMARK 900 RELATED ID: 1AQ1 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 STAUROSPORINE REMARK 900 RELATED ID: 1H0W RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[ CYCLOHEX-3-ENYL]METHOXYPURINE REMARK 900 RELATED ID: 1CKP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 PURVALANOL B REMARK 900 RELATED ID: 1G5S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2)IN REMARK 900 COMPLEX WITH THE INHIBITOR H717 REMARK 900 RELATED ID: 1KE8 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2- REMARK 900 DIHYDRO-3H-INDOL-3 -YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2- YL) REMARK 900 BENZENESULFONAMIDE REMARK 900 RELATED ID: 1PXL RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THEINHIBITOR [4-(2,4- REMARK 900 DIMETHYL-THIAZOL- 5-YL)-PYRIMIDIN-2-YL]-(4-TRIFLUOROMETHYL- PHENYL)- REMARK 900 AMINE REMARK 900 RELATED ID: 1H28 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P107 REMARK 900 RELATED ID: 1H26 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P53 REMARK 900 RELATED ID: 2VTR RELATED DB: PDB REMARK 900 IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(2,6 -DICHLOROBENZOYLAMINO)- REMARK 900 1H-PYRAZOLE-3- CARBOXAMIDE (AT7519), A NOVEL CYCLIN DEPENDENT REMARK 900 KINASE INHIBITOR USING FRAGMENT-BASED X- RAY CRYSTALLOGRAPHY AND REMARK 900 STRUCTURE BASED DRUG DESIGN. REMARK 900 RELATED ID: 1H07 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1E1X RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027 REMARK 900 RELATED ID: 1Y8Y RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1,5-A] REMARK 900 PYRIMIDINE INHIBITOR DBREF 2W17 A 0 0 PDB 2W17 2W17 0 0 DBREF 2W17 A 1 298 UNP P24941 CDK2_HUMAN 1 298 SEQRES 1 A 299 ACE MET GLU ASN PHE GLN LYS VAL GLU LYS ILE GLY GLU SEQRES 2 A 299 GLY THR TYR GLY VAL VAL TYR LYS ALA ARG ASN LYS LEU SEQRES 3 A 299 THR GLY GLU VAL VAL ALA LEU LYS LYS ILE ARG LEU ASP SEQRES 4 A 299 THR GLU THR GLU GLY VAL PRO SER THR ALA ILE ARG GLU SEQRES 5 A 299 ILE SER LEU LEU LYS GLU LEU ASN HIS PRO ASN ILE VAL SEQRES 6 A 299 LYS LEU LEU ASP VAL ILE HIS THR GLU ASN LYS LEU TYR SEQRES 7 A 299 LEU VAL PHE GLU PHE LEU HIS GLN ASP LEU LYS LYS PHE SEQRES 8 A 299 MET ASP ALA SER ALA LEU THR GLY ILE PRO LEU PRO LEU SEQRES 9 A 299 ILE LYS SER TYR LEU PHE GLN LEU LEU GLN GLY LEU ALA SEQRES 10 A 299 PHE CYS HIS SER HIS ARG VAL LEU HIS ARG ASP LEU LYS SEQRES 11 A 299 PRO GLN ASN LEU LEU ILE ASN THR GLU GLY ALA ILE LYS SEQRES 12 A 299 LEU ALA ASP PHE GLY LEU ALA ARG ALA PHE GLY VAL PRO SEQRES 13 A 299 VAL ARG THR TYR THR HIS GLU VAL VAL THR LEU TRP TYR SEQRES 14 A 299 ARG ALA PRO GLU ILE LEU LEU GLY CYS LYS TYR TYR SER SEQRES 15 A 299 THR ALA VAL ASP ILE TRP SER LEU GLY CYS ILE PHE ALA SEQRES 16 A 299 GLU MET VAL THR ARG ARG ALA LEU PHE PRO GLY ASP SER SEQRES 17 A 299 GLU ILE ASP GLN LEU PHE ARG ILE PHE ARG THR LEU GLY SEQRES 18 A 299 THR PRO ASP GLU VAL VAL TRP PRO GLY VAL THR SER MET SEQRES 19 A 299 PRO ASP TYR LYS PRO SER PHE PRO LYS TRP ALA ARG GLN SEQRES 20 A 299 ASP PHE SER LYS VAL VAL PRO PRO LEU ASP GLU ASP GLY SEQRES 21 A 299 ARG SER LEU LEU SER GLN MET LEU HIS TYR ASP PRO ASN SEQRES 22 A 299 LYS ARG ILE SER ALA LYS ALA ALA LEU ALA HIS PRO PHE SEQRES 23 A 299 PHE GLN ASP VAL THR LYS PRO VAL PRO HIS LEU ARG LEU HET ACE A 0 3 HET ACT A1299 4 HET I19 A1300 33 HETNAM ACE ACETYL GROUP HETNAM ACT ACETATE ION HETNAM I19 N-(4-{[(3S)-3-(DIMETHYLAMINO)PYRROLIDIN-1- HETNAM 2 I19 YL]CARBONYL}PHENYL)-5-FLUORO-4-[2-METHYL-1-(1- HETNAM 3 I19 METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-AMINE FORMUL 1 ACE C2 H4 O FORMUL 2 ACT C2 H3 O2 1- FORMUL 3 I19 C24 H30 F N7 O FORMUL 4 HOH *150(H2 O) HELIX 1 1 PRO A 45 LYS A 56 1 12 HELIX 2 2 LEU A 87 SER A 94 1 8 HELIX 3 3 PRO A 100 HIS A 121 1 22 HELIX 4 4 ALA A 170 LEU A 175 1 6 HELIX 5 5 THR A 182 ARG A 199 1 18 HELIX 6 6 SER A 207 GLY A 220 1 14 HELIX 7 7 GLY A 229 MET A 233 5 5 HELIX 8 8 ASP A 247 VAL A 252 1 6 HELIX 9 9 ASP A 256 LEU A 267 1 12 HELIX 10 10 SER A 276 ALA A 282 1 7 HELIX 11 11 HIS A 283 GLN A 287 5 5 SHEET 1 AA 5 PHE A 4 GLY A 11 0 SHEET 2 AA 5 VAL A 17 ASN A 23 -1 O VAL A 18 N ILE A 10 SHEET 3 AA 5 VAL A 29 LYS A 34 -1 O VAL A 30 N ALA A 21 SHEET 4 AA 5 LEU A 76 GLU A 81 -1 O LEU A 78 N LYS A 33 SHEET 5 AA 5 LEU A 66 HIS A 71 -1 N LEU A 67 O VAL A 79 SHEET 1 AB 3 GLN A 85 ASP A 86 0 SHEET 2 AB 3 LEU A 133 ILE A 135 -1 O ILE A 135 N GLN A 85 SHEET 3 AB 3 ILE A 141 LEU A 143 -1 O LYS A 142 N LEU A 134 LINK C ACE A 0 N MET A 1 1555 1555 1.35 CISPEP 1 THR A 72 GLU A 73 0 4.83 CISPEP 2 PRO A 253 PRO A 254 0 13.92 SITE 1 AC1 5 MET A 1 GLU A 2 ASN A 3 ILE A 70 SITE 2 AC1 5 TYR A 179 SITE 1 AC2 2 SER A 106 THR A 290 SITE 1 AC3 14 ILE A 10 VAL A 18 ALA A 31 LYS A 33 SITE 2 AC3 14 VAL A 64 PHE A 80 GLU A 81 LEU A 83 SITE 3 AC3 14 HIS A 84 GLN A 85 ASP A 86 GLN A 131 SITE 4 AC3 14 LEU A 134 ASP A 145 CRYST1 53.542 71.824 71.771 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.018677 0.000000 0.000000 0.00000 SCALE2 0.000000 0.013923 0.000000 0.00000 SCALE3 0.000000 0.000000 0.013933 0.00000 HETATM 1 C ACE A 0 -14.217 33.995 -3.047 1.00 65.77 C HETATM 2 O ACE A 0 -13.449 34.393 -3.916 1.00 65.76 O HETATM 3 CH3 ACE A 0 -15.385 34.831 -2.613 1.00 65.67 C TER 2218 LEU A 298 HETATM 2219 C ACT A1299 14.239 43.706 18.145 1.00 56.30 C HETATM 2220 O ACT A1299 14.334 42.438 18.100 1.00 55.83 O HETATM 2221 OXT ACT A1299 13.101 44.185 17.903 1.00 55.82 O HETATM 2222 CH3 ACT A1299 15.410 44.614 18.461 1.00 55.62 C HETATM 2223 C1 I19 A1300 0.174 28.280 11.709 1.00 41.49 C HETATM 2224 C2 I19 A1300 -0.209 28.230 10.244 1.00 44.80 C HETATM 2225 C3 I19 A1300 -0.297 26.812 9.703 1.00 42.38 C HETATM 2226 N1 I19 A1300 -1.418 29.013 10.059 1.00 46.22 N HETATM 2227 C4 I19 A1300 -2.587 28.746 10.661 1.00 47.19 C HETATM 2228 C5 I19 A1300 -2.919 27.621 11.588 1.00 47.84 C HETATM 2229 N2 I19 A1300 -3.434 29.698 10.275 1.00 48.18 N HETATM 2230 C6 I19 A1300 -2.830 30.594 9.411 1.00 47.74 C HETATM 2231 C7 I19 A1300 -1.529 30.163 9.264 1.00 46.82 C HETATM 2232 C8 I19 A1300 -0.498 30.819 8.397 1.00 44.95 C HETATM 2233 N3 I19 A1300 0.472 30.052 7.883 1.00 43.93 N HETATM 2234 C9 I19 A1300 1.393 30.657 7.119 1.00 44.39 C HETATM 2235 N4 I19 A1300 2.459 29.956 6.522 1.00 43.69 N HETATM 2236 C10 I19 A1300 3.176 28.820 6.934 1.00 42.38 C HETATM 2237 C11 I19 A1300 2.952 28.162 8.123 1.00 43.08 C HETATM 2238 C12 I19 A1300 3.704 27.054 8.459 1.00 43.34 C HETATM 2239 C13 I19 A1300 4.678 26.603 7.588 1.00 43.10 C HETATM 2240 C14 I19 A1300 4.941 27.245 6.391 1.00 42.32 C HETATM 2241 C15 I19 A1300 4.170 28.355 6.087 1.00 41.96 C HETATM 2242 C16 I19 A1300 5.504 25.454 7.926 1.00 43.74 C HETATM 2243 O1 I19 A1300 6.709 25.662 7.960 1.00 44.13 O HETATM 2244 N5 I19 A1300 4.945 24.220 8.153 1.00 45.61 N HETATM 2245 C17 I19 A1300 3.629 23.973 8.678 1.00 46.58 C HETATM 2246 C18 I19 A1300 3.659 22.501 9.075 1.00 49.25 C HETATM 2247 C19 I19 A1300 5.124 22.120 9.256 1.00 49.44 C HETATM 2248 C20 I19 A1300 5.892 23.203 8.551 1.00 47.62 C HETATM 2249 N6 I19 A1300 5.540 22.192 10.697 1.00 52.17 N HETATM 2250 C21 I19 A1300 4.497 21.801 11.684 1.00 49.52 C HETATM 2251 C22 I19 A1300 6.765 21.379 10.948 1.00 52.27 C HETATM 2252 N7 I19 A1300 1.385 31.968 6.837 1.00 44.97 N HETATM 2253 C23 I19 A1300 0.411 32.708 7.359 1.00 44.14 C HETATM 2254 C24 I19 A1300 -0.561 32.179 8.154 1.00 45.43 C HETATM 2255 F1 I19 A1300 -1.501 33.005 8.641 1.00 47.09 F HETATM 2256 O HOH A2001 -7.436 26.021 -7.083 1.00 55.38 O HETATM 2257 O HOH A2002 5.532 25.134 3.574 1.00 51.31 O HETATM 2258 O HOH A2003 -0.808 19.850 -1.387 1.00 61.14 O HETATM 2259 O HOH A2004 -4.246 24.215 11.243 1.00 48.22 O HETATM 2260 O HOH A2005 6.625 28.185 0.460 1.00 47.37 O HETATM 2261 O HOH A2006 4.829 28.587 -4.378 1.00 63.61 O HETATM 2262 O HOH A2007 4.250 45.092 9.159 1.00 44.05 O HETATM 2263 O HOH A2008 -2.057 37.714 -12.173 1.00 54.52 O HETATM 2264 O HOH A2009 2.165 38.697 -8.851 1.00 58.62 O HETATM 2265 O HOH A2010 -20.334 38.997 0.225 1.00 54.79 O HETATM 2266 O HOH A2011 0.910 37.683 1.741 1.00 43.25 O HETATM 2267 O HOH A2012 1.661 38.447 -1.935 1.00 36.62 O HETATM 2268 O HOH A2013 14.689 24.074 7.069 1.00 44.81 O HETATM 2269 O HOH A2014 -27.033 35.794 12.093 1.00 64.66 O HETATM 2270 O HOH A2015 12.630 51.981 24.301 1.00 78.72 O HETATM 2271 O HOH A2016 26.676 38.090 21.130 1.00 59.50 O HETATM 2272 O HOH A2017 -5.041 40.208 13.775 1.00 44.65 O HETATM 2273 O HOH A2018 -6.279 48.524 13.071 1.00 44.79 O HETATM 2274 O HOH A2019 -4.476 41.500 11.548 1.00 41.60 O HETATM 2275 O HOH A2020 -3.749 48.430 15.074 1.00 64.58 O HETATM 2276 O HOH A2021 0.249 48.668 12.853 1.00 50.62 O HETATM 2277 O HOH A2022 5.312 46.823 19.841 1.00 52.57 O HETATM 2278 O HOH A2023 1.455 43.983 8.474 1.00 63.17 O HETATM 2279 O HOH A2024 1.251 46.432 11.993 1.00 41.50 O HETATM 2280 O HOH A2025 -1.155 42.340 11.896 1.00 62.31 O HETATM 2281 O HOH A2026 -4.638 37.655 13.214 1.00 52.29 O HETATM 2282 O HOH A2027 -5.809 43.471 8.907 1.00 39.72 O HETATM 2283 O HOH A2028 -7.112 39.401 0.306 1.00 51.73 O HETATM 2284 O HOH A2029 -16.430 38.838 2.497 1.00 44.21 O HETATM 2285 O HOH A2030 2.033 13.937 23.284 1.00 44.28 O HETATM 2286 O HOH A2031 3.815 18.319 20.089 1.00 69.57 O HETATM 2287 O HOH A2032 -20.848 38.624 3.101 1.00 55.47 O HETATM 2288 O HOH A2033 -0.483 40.922 35.057 1.00 47.59 O HETATM 2289 O HOH A2034 4.633 39.736 4.861 1.00 55.34 O HETATM 2290 O HOH A2035 6.265 37.013 4.726 1.00 51.88 O HETATM 2291 O HOH A2036 8.094 28.377 2.401 1.00 56.88 O HETATM 2292 O HOH A2037 9.414 26.548 5.065 1.00 43.85 O HETATM 2293 O HOH A2038 7.835 34.878 4.342 1.00 48.49 O HETATM 2294 O HOH A2039 14.578 25.812 8.918 1.00 53.37 O HETATM 2295 O HOH A2040 2.592 25.334 11.664 1.00 49.45 O HETATM 2296 O HOH A2041 8.639 21.779 5.395 1.00 60.93 O HETATM 2297 O HOH A2042 12.962 21.118 10.026 1.00 57.88 O HETATM 2298 O HOH A2043 16.459 24.032 18.185 1.00 49.76 O HETATM 2299 O HOH A2044 19.437 28.746 13.866 1.00 52.66 O HETATM 2300 O HOH A2045 25.540 19.810 14.723 1.00 56.28 O HETATM 2301 O HOH A2046 26.305 22.038 19.877 1.00 61.18 O HETATM 2302 O HOH A2047 26.121 25.328 13.762 1.00 53.94 O HETATM 2303 O HOH A2048 21.691 27.131 14.352 1.00 53.72 O HETATM 2304 O HOH A2049 24.529 31.619 21.147 1.00 54.45 O HETATM 2305 O HOH A2050 22.569 35.713 15.802 1.00 53.89 O HETATM 2306 O HOH A2051 22.265 37.788 23.022 1.00 44.56 O HETATM 2307 O HOH A2052 12.859 35.505 11.311 1.00 41.72 O HETATM 2308 O HOH A2053 8.668 43.962 17.158 1.00 54.40 O HETATM 2309 O HOH A2054 10.085 47.814 23.666 1.00 52.65 O HETATM 2310 O HOH A2055 -0.106 44.864 27.612 1.00 46.12 O HETATM 2311 O HOH A2056 24.085 40.182 20.740 1.00 63.11 O HETATM 2312 O HOH A2057 -2.647 44.384 30.003 1.00 60.49 O HETATM 2313 O HOH A2058 -8.606 47.741 26.153 1.00 61.23 O HETATM 2314 O HOH A2059 -6.968 27.024 24.197 1.00 53.73 O HETATM 2315 O HOH A2060 -9.563 36.731 23.890 1.00 50.89 O HETATM 2316 O HOH A2061 -2.008 27.201 25.918 1.00 46.52 O HETATM 2317 O HOH A2062 -0.503 26.176 23.941 1.00 43.32 O HETATM 2318 O HOH A2063 -3.611 23.313 16.814 1.00 58.91 O HETATM 2319 O HOH A2064 -1.866 20.819 18.283 1.00 56.48 O HETATM 2320 O HOH A2065 -1.079 25.555 14.408 1.00 47.53 O HETATM 2321 O HOH A2066 6.311 38.905 6.575 1.00 45.14 O HETATM 2322 O HOH A2067 8.379 41.695 8.478 1.00 52.77 O HETATM 2323 O HOH A2068 8.696 41.221 2.244 1.00 44.96 O HETATM 2324 O HOH A2069 15.342 38.736 14.381 1.00 38.52 O HETATM 2325 O HOH A2070 1.956 41.402 10.227 1.00 46.81 O HETATM 2326 O HOH A2071 -5.246 35.033 13.717 1.00 55.06 O HETATM 2327 O HOH A2072 -3.040 16.396 15.186 1.00 69.32 O HETATM 2328 O HOH A2073 -6.637 14.550 13.074 1.00 71.89 O HETATM 2329 O HOH A2074 -4.276 16.392 23.452 1.00 60.61 O HETATM 2330 O HOH A2075 -0.084 23.546 24.433 1.00 36.51 O HETATM 2331 O HOH A2076 -2.386 22.958 21.220 1.00 69.72 O HETATM 2332 O HOH A2077 6.769 22.324 27.255 1.00 43.06 O HETATM 2333 O HOH A2078 2.137 16.589 21.966 1.00 61.66 O HETATM 2334 O HOH A2079 6.144 21.506 19.880 1.00 58.74 O HETATM 2335 O HOH A2080 -6.222 21.513 27.987 1.00 44.90 O HETATM 2336 O HOH A2081 2.795 23.660 30.147 1.00 44.78 O HETATM 2337 O HOH A2082 -1.533 28.333 28.361 1.00 35.25 O HETATM 2338 O HOH A2083 -4.634 33.000 33.965 1.00 46.42 O HETATM 2339 O HOH A2084 -9.551 25.172 32.279 1.00 51.53 O HETATM 2340 O HOH A2085 -11.979 32.190 29.386 1.00 39.86 O HETATM 2341 O HOH A2086 -11.946 30.936 37.150 1.00 65.63 O HETATM 2342 O HOH A2087 -10.359 33.993 29.428 1.00 50.47 O HETATM 2343 O HOH A2088 -6.274 39.094 31.534 1.00 55.76 O HETATM 2344 O HOH A2089 -0.346 39.566 31.720 1.00 44.65 O HETATM 2345 O HOH A2090 -1.044 30.495 25.026 1.00 42.30 O HETATM 2346 O HOH A2091 8.867 23.708 25.726 1.00 39.78 O HETATM 2347 O HOH A2092 12.351 21.325 19.989 1.00 62.72 O HETATM 2348 O HOH A2093 17.716 25.992 19.527 1.00 51.24 O HETATM 2349 O HOH A2094 20.918 25.388 22.578 1.00 56.12 O HETATM 2350 O HOH A2095 12.229 18.664 29.309 1.00 56.82 O HETATM 2351 O HOH A2096 11.604 16.846 24.452 1.00 70.92 O HETATM 2352 O HOH A2097 0.464 16.984 24.685 1.00 41.85 O HETATM 2353 O HOH A2098 0.299 8.410 25.376 1.00 43.06 O HETATM 2354 O HOH A2099 -0.429 10.216 30.063 1.00 39.51 O HETATM 2355 O HOH A2100 -6.865 21.406 30.223 1.00 46.18 O HETATM 2356 O HOH A2101 -9.956 16.318 29.314 1.00 64.28 O HETATM 2357 O HOH A2102 -5.208 13.235 32.219 1.00 56.29 O HETATM 2358 O HOH A2103 2.262 11.252 34.747 1.00 50.23 O HETATM 2359 O HOH A2104 6.875 25.364 44.003 1.00 46.01 O HETATM 2360 O HOH A2105 -1.387 24.227 50.297 1.00 57.46 O HETATM 2361 O HOH A2106 1.330 33.127 50.171 1.00 55.00 O HETATM 2362 O HOH A2107 4.042 31.989 42.118 1.00 55.98 O HETATM 2363 O HOH A2108 -4.516 32.195 41.059 1.00 51.35 O HETATM 2364 O HOH A2109 -8.149 28.519 48.480 1.00 53.81 O HETATM 2365 O HOH A2110 -13.781 20.940 36.267 1.00 58.70 O HETATM 2366 O HOH A2111 -3.551 19.823 49.496 1.00 45.35 O HETATM 2367 O HOH A2112 -0.836 18.665 46.839 1.00 50.80 O HETATM 2368 O HOH A2113 -0.615 21.305 47.185 1.00 58.59 O HETATM 2369 O HOH A2114 -11.426 16.712 38.722 1.00 61.81 O HETATM 2370 O HOH A2115 6.601 11.954 45.444 1.00 74.58 O HETATM 2371 O HOH A2116 10.440 16.074 45.778 1.00 59.16 O HETATM 2372 O HOH A2117 10.582 17.299 42.070 1.00 48.32 O HETATM 2373 O HOH A2118 19.017 28.572 39.645 1.00 56.92 O HETATM 2374 O HOH A2119 17.823 14.546 39.498 1.00 68.63 O HETATM 2375 O HOH A2120 25.620 30.895 30.839 1.00 45.88 O HETATM 2376 O HOH A2121 21.831 37.588 28.050 1.00 58.18 O HETATM 2377 O HOH A2122 21.997 39.495 29.803 1.00 57.85 O HETATM 2378 O HOH A2123 25.638 31.472 34.480 1.00 51.92 O HETATM 2379 O HOH A2124 16.533 36.389 39.748 1.00 55.11 O HETATM 2380 O HOH A2125 17.407 32.948 38.142 1.00 64.00 O HETATM 2381 O HOH A2126 8.978 29.915 37.867 1.00 56.57 O HETATM 2382 O HOH A2127 9.456 38.518 40.504 1.00 47.23 O HETATM 2383 O HOH A2128 10.976 41.544 36.545 1.00 40.26 O HETATM 2384 O HOH A2129 6.913 28.475 39.360 1.00 70.37 O HETATM 2385 O HOH A2130 6.253 30.464 41.595 1.00 48.16 O HETATM 2386 O HOH A2131 -3.480 34.766 44.204 1.00 56.73 O HETATM 2387 O HOH A2132 0.116 38.265 35.794 1.00 42.80 O HETATM 2388 O HOH A2133 3.155 40.824 37.362 1.00 51.70 O HETATM 2389 O HOH A2134 1.310 37.561 32.939 1.00 36.27 O HETATM 2390 O HOH A2135 4.093 42.310 35.782 1.00 44.06 O HETATM 2391 O HOH A2136 1.053 44.873 32.724 1.00 64.52 O HETATM 2392 O HOH A2137 0.831 40.695 29.430 1.00 33.57 O HETATM 2393 O HOH A2138 1.453 43.367 29.234 1.00 32.57 O HETATM 2394 O HOH A2139 2.199 48.144 23.971 1.00 61.98 O HETATM 2395 O HOH A2140 7.885 47.958 28.936 1.00 59.99 O HETATM 2396 O HOH A2141 16.632 47.361 31.993 1.00 51.46 O HETATM 2397 O HOH A2142 15.137 45.529 28.749 1.00 57.97 O HETATM 2398 O HOH A2143 15.758 47.481 24.693 1.00 55.92 O HETATM 2399 O HOH A2144 21.965 40.161 21.968 1.00 43.50 O HETATM 2400 O HOH A2145 25.766 41.401 24.583 1.00 56.91 O HETATM 2401 O HOH A2146 23.516 40.222 17.777 1.00 45.14 O HETATM 2402 O HOH A2147 19.563 40.139 20.318 1.00 46.97 O HETATM 2403 O HOH A2148 19.020 44.243 12.298 1.00 44.94 O HETATM 2404 O HOH A2149 21.963 38.468 11.722 1.00 41.95 O HETATM 2405 O HOH A2150 19.877 31.195 12.115 1.00 49.61 O CONECT 1 2 3 4 CONECT 2 1 CONECT 3 1 CONECT 4 1 CONECT 2219 2220 2221 2222 CONECT 2220 2219 CONECT 2221 2219 CONECT 2222 2219 CONECT 2223 2224 CONECT 2224 2223 2225 2226 CONECT 2225 2224 CONECT 2226 2224 2227 2231 CONECT 2227 2226 2228 2229 CONECT 2228 2227 CONECT 2229 2227 2230 CONECT 2230 2229 2231 CONECT 2231 2226 2230 2232 CONECT 2232 2231 2233 2254 CONECT 2233 2232 2234 CONECT 2234 2233 2235 2252 CONECT 2235 2234 2236 CONECT 2236 2235 2237 2241 CONECT 2237 2236 2238 CONECT 2238 2237 2239 CONECT 2239 2238 2240 2242 CONECT 2240 2239 2241 CONECT 2241 2236 2240 CONECT 2242 2239 2243 2244 CONECT 2243 2242 CONECT 2244 2242 2245 2248 CONECT 2245 2244 2246 CONECT 2246 2245 2247 CONECT 2247 2246 2248 2249 CONECT 2248 2244 2247 CONECT 2249 2247 2250 2251 CONECT 2250 2249 CONECT 2251 2249 CONECT 2252 2234 2253 CONECT 2253 2252 2254 CONECT 2254 2232 2253 2255 CONECT 2255 2254 MASTER 802 0 3 11 8 0 7 6 2396 1 41 23 END